Elsevier

Insulin

Volume 3, Issue 1, January 2008, Pages 31-36
Insulin

Quality of Life and Insulin Therapy in Type 2 Diabetes Mellitus

https://doi.org/10.1016/S1557-0843(08)80009-7Get rights and content

Abstract

Background: A frequently cited barrier to insulin use in type 2 diabetes mellitus (DM) is concern about the adverse effects on quality of life. Results of studies in this area have been mixed, with insulin use showing decreased, enhanced, or no impact on quality of life.

Objective: The purpose of this paper is to discuss the state of the science regarding the effects of insulin on quality of life and to present strategies providers can implement in their clinical practices to decrease barriers to insulin use among patients with type 2 DM.

Methods: An English-language MEDLINE search of the current literature using the terms insulin and quality of life was conducted for this article.

Results: Although patient-identified concerns regarding insulin use represent some aspects of quality of life, study results have been mixed. However, 2 large studies examining the use of insulin glargine and its effects on quality of life found that glargine was associated with significantly greater improvements in quality of life when added to oral antidiabetic agents (OADs) than was the use of OADs alone. Another study examined the effects of intensive multi- therapy (monthly visits, self-management diabetes education, and medication adjustments) on quality of life among patients with type 2 DM and found that quality-of-life scores improved among patients who initiated insulin therapy during the trial. The effects of insulin delivery systems on quality of life have also been assessed. In these studies, patients preferred insulin pens over vials and syringes and inhaled over injected insulin. Health care providers can facilitate acceptance of insulin by employing strategies to help patients overcome psychological barriers to insulin therapy.

Conclusions: Although patient concerns about the effects of insulin use are legitimate, insulin therapy is often needed to achieve treatment targets. Providers can reduce the impact on quality of life by addressing barriers, helping patients improve metabolic control, and providing ongoing information and support.

References (39)

  • M Peyrot et al.

    Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study

    Diabetes Care

    (2005)
  • TM Wallace et al.

    Poor glycaemic control in type 2 diabetes: A conspiracy of disease, suboptimal therapy and attitude

    QJM

    (2000)
  • JJ de Sonnaville et al.

    Well-being and symp-toms in relation to insulin therapy in type 2 diabetes

    Diabetes Care

    (1998)
  • M Haque et al.

    Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Capetown

    S Afr Med J

    (2005)
  • LM Hunt et al.

    NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance

    Diabetes Care

    (1997)
  • BH Wolfenbuttal et al.

    Determinants of injecting insulin in elderly patients with type 2 diabetes mellitus

    Patient Educ Couns

    (1993)
  • RR Rubin et al.

    Quality of life and diabetes

    Diabetes Metab Res Rev

    (1999)
  • JG Boyer et al.

    The development of an instrument for assess-ing the quality of life for people with diabetes

    Med Care

    (1997)
  • DJ Wexler et al.

    Correlates of health-related quality of life in type 2 diabetes

    Diabetologia

    (2006)

    • Cited by (0)

    View full text
    Copyright © 2008 Published by Elsevier Inc.